Table 3 Surgical information and pathological status after surgery
From: Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Location, cases | |
LU LL RU RM RL | 22 9 25 3 16 |
Surgical approach | |
VATS Open | 51(68%) 24(32%) |
Surgical resection | |
Lobectomy Bilobectomy Sleeve lobectomy Pneumonectomy | 58(77%) 7 (9%) 8 (11%) 2(3%) |
Operative time, min | |
Median (range) | 130(70–240) |
Estimated blood loss, ml | |
Median (range) | 80(20–500) |
Length of postoperative hospitalization, days | |
Median (range) | 5.2(3–16) |
Pathological response | |
PCR non-PCR mPR non-mPR | 27(36%) 48(64%) 45(60%) 30(40%) |
Nodal status after neo-adjuvant therapy | |
N2 clearance N2 residual N1 clearance N1 residual | 34(67%) 15(33%) 20(77%) 6 (23%) |
Postoperative complications | |
Prolonged air leak > 5 days Pneumonia Pleural effusion duration > 5 days Atrial fibrillation Recurrent nerve paralysis Chylothorax Postoperative bleeding | 12(16%) 5 (7%) 8 (11%) 8 (11%) 2 (3%) 1 (1%) 1 (1%) |